Business

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update

EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today’s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements

articleNeuroone Medical Technologies CorporationMarch 18, 20255/company/neuroone-medical-technologies-corp/news/neuroone-ceo-dave-rosa-discusses-171200477
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update

About this update from Neuroone Medical Technologies Corporation

[{"type":"image","alt":"NeuroOne Medical Technologies Corporation","displaySize":"","headline":null,"caption":"NeuroOne Medical Technologies Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/819fe13d4f4c15d1a815f2aae4dd578b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pp0tg2T4IB9hXCYxVLu0sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/819fe13d4f4c15d1a815f2aae4dd578b","width":300,"height":48}},"lazy":false},{"type":"text","content":"EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today’s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne’s breakthrough OneRF® Ablation System.","length":598,"tagName":"p"},{"type":"text","content":"The full interview can be viewed online here.","length":45,"tagName":"p"},{"type":"text","content":"Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer a promising solution.","length":279,"tagName":"p"},{"type":"text","content":"NeuroOne’s OneRF® ablation system, is the first and only FDA 510(k)-cleared device capable of both recording brain activity and performing an RF ablation using the same device. The system has three main components: an electrode that stimulates, records and monitors brain activity with the capability to also perform an ablation, a temperature probe, and a radio frequency heat generator system.","length":395,"tagName":"p"},{"type":"text","content":""It was my pleasure to take part in this engaging conversation with Elizabeth Hart and Dr. Clark about the latest treatment options for epilepsy. The OneRF® system represents a significant advancement, offering a more efficient and precise approach for ...

More updates from Neuroone Medical Technologies Corporation

NeuroOne Medical Technologies Corporationpatient outcomesneurological disordersRF ablationDave RosaJessica Clarkbrain activityNMTCablation therapy